Article
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
PloS one - 3 Nov 2010
Kompier Lucie C, Lurkin Irene, van der Aa Madelon N M, van Rhijn Bas W G, van der Kwast Theo H, Zwarthoff Ellen C
Abstract excerpt
BACKGROUND: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to stratify patients based on mutations in relevant oncogenes. Patients with non-muscle-invasive bladder cancer (NMI-BC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.